Ty21a
Ty21a
Ty21a (pronounced: /taɪ twɛnti wʌn eɪ/) is a live attenuated bacterial vaccine used to prevent typhoid fever. It was developed in the 1970s by scientists at the University of Maryland, including Myron M. Levine and Robert Edelman.
Etymology
The name "Ty21a" is derived from the strain of Salmonella typhi that the vaccine is based on. The "21a" indicates that it is a variant of the 21st strain of Salmonella typhi that was studied.
Usage
Ty21a is administered orally, either as a liquid suspension or in capsule form. It is typically given in a series of four doses, spaced two days apart. The vaccine stimulates the immune system to produce an immune response against Salmonella typhi, thereby providing protection against typhoid fever.
Related Terms
- Typhoid fever: An infectious disease caused by Salmonella typhi, characterized by fever, headache, and abdominal pain. Ty21a is used to prevent this disease.
- Salmonella typhi: The bacterium that causes typhoid fever. Ty21a is a variant of this bacterium.
- Bacterial vaccine: A vaccine that is made from bacteria or components of bacteria. Ty21a is a type of bacterial vaccine.
- Myron M. Levine: A scientist who was instrumental in the development of Ty21a.
- Robert Edelman: A scientist who was instrumental in the development of Ty21a.
External links
- Medical encyclopedia article on Ty21a
- Wikipedia's article - Ty21a
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski